Xencor

Uniquely Versatile Bispecific Antibodies for Cancer and Autoimmune

Antibodies Engineered with Purpose: Xencor’s Fc domain technology supercharges antibody therapies by extending half-life, enhancing immune activation, and enabling precise targeting. It powers a new wave of biologics designed for superior efficacy against complex diseases.
I&I is Red Hot. How do Bispecific Antibodies play into it? Xencor’s plug-and-play antibody approach allows for the extension into multiple disease areas beyond oncology, including autoimmune and inflammatory diseases, as evidenced by multiple newly announced T-cell engager programs with upcoming clinical milestones.

Validated Commercial Platform: Xencor’s protein engineering platform is validated through multiple commercially approved drugs and continues to be a highly sought after partner for novel drug development (over 10+ select partnered/licensed programs and 8 owned programs in various disease areas).

Key Events in 1H 2025: Phase 1/2 Data and Study Initiations Across Immunology and Oncology Programs
- Immunology Portfolio
  - XmAb942: SAD readout in inflammatory bowel diseases
  - Plamotamab: Initiation of Phase 1/2 study in rheumatoid arthritis
- Oncology Portfolio
  - XmAb819 and XmAb808: Initiation of dose expansion in ccRCC and solid tumors.
  - Vudalimab: Mono and combo cohort expansion readout in mCRPC. Evaluate chemo combination safety in NSCLC.